Sensus Healthcare Inc (NASDAQ:SRTS) was the target of a significant increase in short interest during the month of October. As of October 31st, there was short interest totalling 46,100 shares, an increase of 5.7% from the September 30th total of 43,600 shares. Currently, 0.4% of the shares of the company are sold short. Based on an average daily volume of 15,900 shares, the days-to-cover ratio is presently 2.9 days.
Institutional investors and hedge funds have recently modified their holdings of the business. Wells Fargo & Company MN purchased a new stake in Sensus Healthcare in the second quarter worth approximately $30,000. Susquehanna International Group LLP boosted its stake in Sensus Healthcare by 69.9% in the second quarter. Susquehanna International Group LLP now owns 27,492 shares of the company’s stock worth $152,000 after buying an additional 11,311 shares in the last quarter. Essex Investment Management Co. LLC purchased a new stake in Sensus Healthcare in the third quarter worth approximately $540,000. BlackRock Inc. boosted its stake in Sensus Healthcare by 40.7% in the second quarter. BlackRock Inc. now owns 103,643 shares of the company’s stock worth $574,000 after buying an additional 29,990 shares in the last quarter. Finally, Heartland Advisors Inc. boosted its stake in Sensus Healthcare by 150.0% in the second quarter. Heartland Advisors Inc. now owns 375,000 shares of the company’s stock worth $2,078,000 after buying an additional 225,000 shares in the last quarter. 9.72% of the stock is owned by institutional investors and hedge funds.
Shares of SRTS traded down $0.03 during midday trading on Friday, hitting $3.51. 52,100 shares of the company traded hands, compared to its average volume of 23,834. The firm has a market cap of $58.40 million, a P/E ratio of -25.07 and a beta of -0.41. The stock has a 50-day moving average of $5.43 and a 200-day moving average of $5.64. Sensus Healthcare has a one year low of $3.46 and a one year high of $9.23.
Sensus Healthcare (NASDAQ:SRTS) last issued its earnings results on Wednesday, November 6th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.05) by $0.01. The business had revenue of $5.84 million during the quarter, compared to analyst estimates of $7.77 million. Sensus Healthcare had a negative return on equity of 9.78% and a negative net margin of 9.83%. On average, equities research analysts predict that Sensus Healthcare will post -0.16 earnings per share for the current fiscal year.
Several equities research analysts have commented on SRTS shares. Maxim Group set a $11.00 price objective on shares of Sensus Healthcare and gave the company a “buy” rating in a report on Friday, August 9th. B. Riley downgraded shares of Sensus Healthcare from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $14.00 to $5.50 in a report on Thursday, November 7th. TheStreet raised shares of Sensus Healthcare from a “d+” rating to a “c-” rating in a report on Monday, August 26th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Sensus Healthcare in a report on Thursday, November 7th. Finally, ValuEngine downgraded shares of Sensus Healthcare from a “buy” rating to a “hold” rating in a report on Thursday, October 17th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average target price of $8.30.
Sensus Healthcare Company Profile
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.